Nanobiotix S.A. (EPA:NANO)
France · Delayed Price · Currency is EUR | Market Cap | 2.14B +1,346.0% |
| Revenue (ttm) | 32.59M |
| Net Income | -23.96M |
| EPS | -0.50 |
| Shares Out | 48.50M |
| PE Ratio | n/a |
| Forward PE | 11,836.68 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 351,953 |
| Average Volume | 282,067 |
| Open | 44.00 |
| Previous Close | 44.10 |
| Day's Range | 42.74 - 47.60 |
| 52-Week Range | 3.23 - 47.60 |
| Beta | 0.58 |
| RSI | 78.87 |
| Earnings Date | May 22, 2026 |
About Nanobiotix
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Th... [Read more]
Financial Performance
Financial StatementsNews
Nanobiotix announces FDA acceptance of NANORAY-312 study protocol amendment
Nanobiotix (NBTX) announced FDA acceptance of a protocol amendment to the ongoing pivotal NANORAY-312 study. This protocol amendment, submitted by NANORAY-312 global sponsor Johnson & Johnson (JNJ), e...
Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study
PARIS and CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approa...
Nanobiotix price target raised to $30 from $3.50 at UBS
UBS raised the firm’s price target on Nanobiotix (NBTX) to $30 from $3.50 and keeps a Neutral rating on the shares. Shares have surged over the past year on improved
Nanobiotix Announces Positive Preclinical Data For Nanoprimer In LNP-DNA Delivery
(RTTNews) - Nanobiotix S.A.(NBTX), a late-stage clinical biotechnology company, announced on Monday preclinical data for the Nanoprimer platform in sequence with lipid nanoparticle-delivered recombina...
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
Preclinical evaluation in mice assessed the potential of the Nanobiotix Nanoprimer to overcome common barriers faced by lipid nanoparticle(“LNP”)-delivered therapies related to rapid liver clearance P...
Nanobiotix price target raised to EUR 34 from EUR 32 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Nanobiotix (NBTX) to EUR 34 from EUR 32 and keeps a Buy rating on the shares. The firm says
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) In accordance with...
Nanobiotix price target raised to $36 from $26 at Guggenheim
Guggenheim raised the firm’s price target on Nanobiotix (NBTX) to $36 from $26 and keeps a Buy rating on the shares. The firm is updating its model to reflect second
Nanobiotix price target raised to $37 from $26 at Leerink
Leerink analyst Jonathan Chang raised the firm’s price target on Nanobiotix (NBTX) to $37 from $26 and keeps an Outperform rating on the shares after the company reported Q4 results
Nanobiotix Earnings Call Transcript: H2 2025
Collaboration with J&J advanced NBTXR3 development in major oncology indications, while a strategic licensing amendment and non-dilutive financing improved financials, reducing net loss by 65% and extending cash runway into 2028. Key clinical data readouts are expected in 2026–2027.
Nanobiotix FY25 Net Loss Narrows; Expects Cash Runway Through Early 2028; Stock Down
(RTTNews) - Nanobiotix S.A. (NBTX), a late-clinical-stage biotechnology company, reported financial results for the year ended December 31, 2025, reflecting a narrower net loss and provided cash runwa...
NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results
Global development program for JNJ-1900 (NBTXR3) proceeded as planned, building toward opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck can...
Nanobiotix price target raised to EUR 32 from EUR 23 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Nanobiotix (NBTX) to EUR 32 from EUR 23 and keeps a Buy rating on the shares after the company
Nanobiotix presents first data from CONVERGE study
Nanobiotix (NBTX) announced the presentation of first data from the CONVERGE study, a Johnson & Johnson (JNJ)-sponsored randomized Phase 2 clinical trial evaluating potential first-in-class Nanoradioe...
NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026
Conference call and webcast scheduled for Wednesday, April 1st, 2026, at 8:00 am EDT / 2:00 pm CEST Conference call and webcast scheduled for Wednesday, April 1st, 2026, at 8:00 am EDT / 2:00 pm CEST
Cancer Drug Developer Nanobiotix Denies Any Active Takeover Process
The stock's movement follows a statement clarifying that there is no ongoing process or assessment for a takeover, which has helped to stabilize investor sentiment as broader markets are experiencing ...
Nanobiotix (NBTX) Addresses Takeover Rumors
Nanobiotix (NBTX) Addresses Takeover Rumors
Nanobiotix Clarifies About Recent Media Speculations Regarding Potential Takeover, Stock Up
(RTTNews) - Nanobiotix S.A. (NBTX) issued a statement on Wednesday in response to recent media speculation concerning intentions for a potential public takeover.
Nanobiotix says ‘no such intention’ for company to acquire control
Nanobiotix (NBTX) issued the following statement in response to recent media speculation concerning intentions for a potential public take-over: “Nanobiotix states that, to the best of its knowledge, ...
NANOBIOTIX Statement Regarding Recent Media Speculation
PARIS and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approa...
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
NANOBIOTIX to Participate in Investor Conferences in March
PARIS and CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approac...
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
Nanobiotix (NBTX) Sees Significant Price Target Increase by Guggenheim | NBTX Stock News
Nanobiotix (NBTX) Sees Significant Price Target Increase by Guggenheim | NBTX Stock News
Nanobiotix initiated with a Buy at TD Cowen
TD Cowen initiated coverage of Nanobiotix (NBTX) with a Buy rating and no price target Nanobiotix’s physics-based platform technologies have broad applicability free of biological constraints, the ana...